The 2009 ACOG Practice Bulletin reported that “hereditary cancer risk assessment should be a part of routine Ob/Gyn practice.”1 As specialists in women’s health, this is our responsibility. Though it may be unfamiliar to many practitioners, the process of cancer risk stratification can be efficient and effective. Using protocol-driven evaluation of cancer susceptibility, personal and family risk factors, and genetic testing, we are now able to create risk profiles and management strategies that demonstrate proven reduction in cancer morbidity and mortality.
Hereditary Cancer Risk Assessment in Obstetrics and Gynecology: The Evolving Standard of Care
Richard P. Frieder, MD, Medical Director, Cancer Genes Cancer Risk Assessment and Prevention Center of Santa Monica, Santa Monica, CA; Assistant Clinical Professor, Department of Obstetrics and Gynecology; David Geffen School of Medicine, UCLA, Los Angeles, CA.
Steven M. Berlin, MD, St. Joseph Medical Center, Towson, MD; Sinai Hospital, Baltimore, MD.
Dr. Frieder reports that he is a consultant and on the speakers' bureau for Myriad Genetics, Inc, and that he is a consultant for Phenogen Sciences, Inc; Perlegen Sciences, Inc; and Genetic Technologies Group.
Dr. Berlin reports that he is on the speakers' bureaus for Myriad Genetics, Inc and Qiagen.